CO6801728A2 - Formulación de lipomosas adecuada para tratar o prevenir la tuberculosis - Google Patents

Formulación de lipomosas adecuada para tratar o prevenir la tuberculosis

Info

Publication number
CO6801728A2
CO6801728A2 CO13158421A CO13158421A CO6801728A2 CO 6801728 A2 CO6801728 A2 CO 6801728A2 CO 13158421 A CO13158421 A CO 13158421A CO 13158421 A CO13158421 A CO 13158421A CO 6801728 A2 CO6801728 A2 CO 6801728A2
Authority
CO
Colombia
Prior art keywords
lipomoses
adequate
formulation
treat
prevent tuberculosis
Prior art date
Application number
CO13158421A
Other languages
English (en)
Inventor
Pere Joan Cardona
Isabel Amat
Blanca Reyes
Ariadna Selga
Merce Amat
Original Assignee
Archivel Farma Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP11150072A external-priority patent/EP2471511A1/en
Application filed by Archivel Farma Sl filed Critical Archivel Farma Sl
Publication of CO6801728A2 publication Critical patent/CO6801728A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • A61K31/06Phenols the aromatic ring being substituted by nitro groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • C12N1/205Bacterial isolates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/32Mycobacterium

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CO13158421A 2011-01-04 2013-07-04 Formulación de lipomosas adecuada para tratar o prevenir la tuberculosis CO6801728A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11150072A EP2471511A1 (en) 2011-01-04 2011-01-04 Liposome formulation suitable for treating or preventing tuberculosis
EP11183487 2011-09-30

Publications (1)

Publication Number Publication Date
CO6801728A2 true CO6801728A2 (es) 2013-11-29

Family

ID=45509459

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13158421A CO6801728A2 (es) 2011-01-04 2013-07-04 Formulación de lipomosas adecuada para tratar o prevenir la tuberculosis

Country Status (18)

Country Link
US (1) US9877917B2 (es)
EP (1) EP2661253B1 (es)
JP (1) JP6096675B2 (es)
KR (1) KR101820026B1 (es)
CN (2) CN103796640A (es)
BR (1) BR112013017267B1 (es)
CA (1) CA2823747C (es)
CO (1) CO6801728A2 (es)
ES (1) ES2631556T3 (es)
HU (1) HUE032409T2 (es)
IL (1) IL227338B (es)
LT (1) LT2661253T (es)
MX (1) MX341918B (es)
PL (1) PL2661253T3 (es)
RU (1) RU2648842C2 (es)
SI (1) SI2661253T1 (es)
WO (1) WO2012093137A1 (es)
ZA (1) ZA201305697B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103720657B (zh) * 2013-11-19 2017-01-04 广东丸美生物技术股份有限公司 一种可变形脂质体的制备方法,及其制备的可变性脂质体
JP2016163851A (ja) * 2015-03-06 2016-09-08 国立大学法人福井大学 コンポジット型可溶化ナノリポソーム及びその製造方法
RU2631607C1 (ru) * 2016-11-22 2017-09-25 Владислав Николаевич Ласкавый Средство для профилактики лейкоза крупного рогатого скота и способ его применения
GB201707700D0 (en) * 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
CN109675059A (zh) * 2019-01-23 2019-04-26 青岛大学 一种类杆菌脂质体及其制备方法与应用
US11202823B2 (en) * 2019-04-05 2021-12-21 Northwestern University Multi-subunit vaccines to elicit both MHC- and CD1-restricted T cell responses
WO2023062066A1 (en) * 2021-10-14 2023-04-20 Archivel Farma, S.L. Liposome formulations for treatment of active tuberculosis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE395428T1 (de) * 1995-02-22 2008-05-15 Adcock Ingram Ltd Verfahren zur isolierung und reinigung von lipidezellwandkomponenten
GB9813100D0 (en) 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
AU2002314358C1 (en) 2001-07-04 2009-03-26 The Secretary Of State For Health Mycobacterial antigens expressed during latency
BR0103887C1 (pt) * 2001-07-17 2005-11-08 Univ Minas Gerais Composições imunogênicas contendo microesferas biodegradáveis encapsulando antìgenos, vetores gênicos e adjuvantes
ES2231037B1 (es) * 2003-10-31 2005-12-16 Archivel Technologies, Sl Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos.
JP2008505106A (ja) * 2004-07-01 2008-02-21 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア ハイスループットプロテオミクス
ES2381492T3 (es) 2005-04-29 2012-05-28 Glaxosmithkline Biologicals Sa Procedimiento de prevención o tratamiento de infección por M. tuberculosis
CN101283085A (zh) * 2005-08-11 2008-10-08 哈佛大学的校长及成员们 用于干燥细胞形式的方法和组合物
US20070059318A1 (en) * 2005-08-15 2007-03-15 Balu-Iyer Sathy V Lipid nano particulates containing antigens as cancer vaccines
ES2564241T3 (es) * 2005-12-02 2016-03-21 Glaxosmithkline Biologicals Sa Nanopartículas para su uso en composiciones inmunogénicas
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
AU2006342615B8 (en) 2006-04-20 2012-07-05 Tokai University Educational System Therapeutic agent for allergy containing liposome having oligosaccharide on its surface
DK2076244T3 (en) 2006-10-10 2017-02-27 Jina Pharmaceuticals Inc Aqueous systems for the preparation of lipid-based pharmaceutical compounds; compositions, methods and uses thereof
ES2307402B1 (es) 2006-10-30 2009-09-30 Archivel Farma, S.L. Vacuna profilactica contra la tuberculosis.
BRPI0705630F8 (pt) * 2007-12-12 2022-01-18 Univ Estadual Campinas Unicamp Processo de produção de vacina gênica lipossomal, vacina gênica lipossomal e uso da mesma
CN101969976A (zh) * 2008-01-11 2011-02-09 美国政府健康与人类服务部秘书处 针对分枝杆菌的多肽疫苗和接种策略
ES2335177B1 (es) 2008-09-19 2011-02-28 Archivel Farma, S.L. Agente inmunoterapeutico apropiado para la profilaxis primaria de la tuberculosis.
WO2010121618A1 (en) 2009-04-24 2010-10-28 Statens Serum Institut A tuberculosis tb vaccine to prevent reactivation
CN106822882A (zh) 2010-12-14 2017-06-13 葛兰素史密丝克莱恩生物有限公司 分枝杆菌抗原组合物

Also Published As

Publication number Publication date
ES2631556T3 (es) 2017-09-01
IL227338B (en) 2019-01-31
CN107296793A (zh) 2017-10-27
JP2014501768A (ja) 2014-01-23
WO2012093137A1 (en) 2012-07-12
CA2823747C (en) 2019-07-23
EP2661253A1 (en) 2013-11-13
LT2661253T (lt) 2017-05-25
CN103796640A (zh) 2014-05-14
US20150050327A1 (en) 2015-02-19
SI2661253T1 (sl) 2017-07-31
ZA201305697B (en) 2014-07-30
WO2012093137A9 (en) 2012-12-27
US9877917B2 (en) 2018-01-30
MX341918B (es) 2016-09-07
HUE032409T2 (en) 2017-09-28
CA2823747A1 (en) 2012-07-12
EP2661253B1 (en) 2017-04-19
BR112013017267A2 (pt) 2018-01-09
IL227338A0 (en) 2013-09-30
RU2648842C2 (ru) 2018-03-28
PL2661253T3 (pl) 2017-08-31
KR101820026B1 (ko) 2018-01-18
BR112013017267A8 (pt) 2018-11-06
BR112013017267B1 (pt) 2021-06-22
MX2013007855A (es) 2013-10-25
KR20140021538A (ko) 2014-02-20
RU2013136379A (ru) 2015-02-10
JP6096675B2 (ja) 2017-03-15

Similar Documents

Publication Publication Date Title
CO6791604A2 (es) Compuesto para liberación controlada de agentes de tratamiento de pozos
CO7061082A2 (es) Compuestos para tratar la artrofia muscular espinal
CO7061086A2 (es) Combinaciones de compuestos activos
CO6811868A2 (es) Combinaciones de principios activos
CO6920291A2 (es) 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idhmutante
CO6930363A2 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
BR112015002704A2 (pt) superfícies sólidas e tratamentos antimicrobianos e processos para preparar os mesmos
CL2015001157A1 (es) Composiciones y métodos para tratar proteinopatías.
BR112013033444A2 (pt) formulações para terapia de ferida
BR112013033720A2 (pt) método para tratar eczema
CO6791602A2 (es) Métodos y sistemas para el tratamiento de pozos
BR112013024401A2 (pt) métodos e composições para o tratamento do transtorno do déficit de atenção
BR112014006702A2 (pt) método para tratar osteoporose
BR112014006291A2 (pt) composição e utilização da composição
CO6801728A2 (es) Formulación de lipomosas adecuada para tratar o prevenir la tuberculosis
BR112015002681A2 (pt) método para tratar um paciente e kit
BR112014013682A2 (pt) composição para cuidado pessoal
BR112013008528A2 (pt) métodos para tratar psoríase
DK2522342T3 (da) Topisk formulering til behandling af hyperkeratonisk hud
CO6791617A2 (es) Combinaciones de compuestos activos
CO6801718A2 (es) Composición terapéutica para el tratamiento de glioblastoma
CL2015001865A1 (es) Solución para preservar conductos vasculares
BR112013030370A2 (pt) compostos de quinona para tratamento de doenças mediadas por ape1
BR112014022694A2 (pt) novos métodos e composições para o tratamento de doença
ES2973957T3 (es) Métodos para tratar y monitorizar el estado de un cáncer